Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07710768 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

Name: A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight — clinical trial record (NCT07710768)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorNovo Nordisk A/S

Started2026-07-15

View on ClinicalTrials.gov ↗

The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.

Amendment history 1 change detected by DataLookout

2026-08-19

Recruitment opened

Trial Details

NCT Number	NCT07710768
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Overweight
Enrollment	44 participants
Start Date	2026-07-15
Primary Completion	2027-04-07 (estimated)
Study Completion	2027-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-18